Monday, May 3, 2021

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

 Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp’s clinical trial activities and will strengthen Tryp’s capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials and is the leading provider of psychotherapeutic training for health professionals who administer psychedelic compounds to patients. In the announcement, Fluence noted that it looks forward to working with Tryp in conducting important research that could be used to develop treatment options for patients suffering from chronic pain, eating disorders and other conditions. Tryp’s collaboration with Fluence will be initially focused on supporting Tryp’s upcoming Phase 2a clinical trial for eating disorders. “In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in psychotherapy design and training,” said Tryp president and chief science officer Jim Gilligan, PhD, in the press release. “Psychotherapy is an essential component of the effective administration of our innovative psilocybin formulations for the chronic pain and eating disorder indications that we are pursuing. Fluence’s experience with training hundreds of clinicians combined with the training protocol they are creating with Tryp will help create a safer and more effective treatment protocol for our clinical trials and ultimately for patients suffering from these conditions.”

To view the full press release, visit https://ibn.fm/G1X5u

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to Tare available in the company’s newsroom at https://ibn.fm/TRYPF

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: